23 Oct TibuSHIELD HS Study
Study Description
The purpose of this study is to evaluate the effect of tibulizumab in adults with Hidradenitis Suppurativa.
Tibulizumab is an experimental drug, which means it has not been approved by the Food and Drug Administration (FDA). This means the safety and effectiveness of this experimental drug is still being studied.
Participation will start with a 30-day screening period, followed by 16 weeks of taking tibulizumab or placebo twice in the first month, then once a month after; followed by a 16-week period of taking tibulizumab once a month. There will be an 8-week time period to follow-up for safety. During these visits participants may have a physical exam, blood draw, have skin examined for lesions and those present counted, and asked to fill out a diary, questionnaires and surveys. Participants will receive compensation for taking part in the study and reimbursement for travel.
Participant Eligibility
• Be at least 18 years old
• Your HS has not gotten better with antibiotic treatment, or you are unable to use antibiotics to treat your HS.
• No prior use of a medicine called secukinumab, ixekizumab, or bimekizumab
Contact
Camila Marquez
(206) 543-5312
Additional Study Details
Full Study Title
A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Hidradenitis Suppurativa (TibuSHIELD)
Investigator(s)
Dr. Vivian Shi
Accepts Healthy Volunteers?
No
Study Site(s)
University of Washington
1959 NE Pacific St.
Seattle, Washington 98195
